AI summary · may contain errors
Once-weekly tirzepatide plus healthy lifestyle intervention in adolescents aged 12 to <18 with obesity or overweight and complications reduced BMI by 18.5% at week 72 versus 0.5% with placebo.
Moving in JAMA Pediatrics, JAMA, The Lancet Diabetes & Endocrinology, Aging Cell, Diabetes Care, medRxiv and Nature Medicine.
Rebuilt
Nothing in this topic has moved yet this week.
Newest first · last 60 days
AI summary · may contain errors
Once-weekly tirzepatide plus healthy lifestyle intervention in adolescents aged 12 to <18 with obesity or overweight and complications reduced BMI by 18.5% at week 72 versus 0.5% with placebo.
AI summary · may contain errors
In adults with overweight or obesity without diabetes in REDEFINE 9, once-weekly cagrilintide-semaglutide 1·7 mg each and 1·0 mg each reduced bodyweight by about 20% at week 68 versus about 2% with placebo.
AI summary · may contain errors
Retatrutide 12 mg delivered the largest placebo-adjusted 52-week weight reduction in adults with overweight or obesity, at -19.80 percentage points (95% CrI -21.81 to -17.78).
AI summary · may contain errors
In a cohort of youths aged 12–21 years with overweight or obesity, glucagon-like peptide-1 receptor agonist therapy is explored for its association with biliary outcomes.
AI summary · may contain errors
In US children, obesity affects 15% of ages 2–5 and 22% of ages 6–11, and is linked to dyslipidemia, hypertension, steatotic liver disease, and obstructive sleep apnea.
AI summary · may contain errors
In ARMMS-T2D, 58% of 166 participants randomized to metabolic-bariatric surgery achieved type 2 diabetes remission versus 3% with medical-lifestyle management over a median 11-year follow-up.
Journals this month
Topics moving, week to 17 Nov 2026
By field